Purchase of AAA Netspot Ga-68 Dotatate Kits for Radio-Pharmaceutical Preparation

About

The Royal Marsden NHS Foundation Trusts awarded a contract to IEL for the purchase of AAA Netspot (gallium Ga 68 dotatate) 40 microgram kits, a radioactive diagnostic agent used with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumours.

The contract value was AUD 400,000.

Netspot is a somatostatin analogue that demonstrates excellent uptake and in vivo stability, with rapid tissue penetration, binding, and clearance, improving the speed and resolution of picture acquisition while reducing patient radiation dose.

The use of a Ga-68 generator also enables on-site production of Ga-68 PSMA, providing flexibility of service and reducing reliance on outsourced companies for delivery of radiopharmaceuticals.

As the vial is multidose, the Trust has a high throughput of patients prescribed this scan; failure to order in the quantities required would result in increased waiting lists and delays to the service.

The product is licensed in the USA but unlicensed in the UK, and can only be sourced in the UK from Imaging Equipment Ltd.

There is no other available treatment as effective on the NHS, as Ga-68 dotatate scans can be used in PET imaging, which provides greater resolution and speed of imaging and therefore diagnosis of neuroendocrine tumours.